The disease characteristics of patients both with IgA nephropathy and diabetes mellitus
10.3760/cma.j.issn.1001-7097.2018.12.002
- VernacularTitle:IgA肾病合并糖尿病患者的临床病理改变特点
- Author:
Xiaoqing LONG
1
;
Yaling ZHAI
;
Yingzi WANG
;
Yanna DOU
;
Genyang CHENG
;
Jing XIAO
;
Zhanzheng ZHAO
;
Xuejun WEN
Author Information
1. 郑州大学第一附属医院肾内科 郑州大学肾脏病研究所
- Keywords:
Glomerulonephritis,IgA;
Diabetes mellitus;
Prognosis;
Disease characteristics
- From:
Chinese Journal of Nephrology
2018;34(12):887-892
- CountryChina
- Language:Chinese
-
Abstract:
Objective To sum up and analyze the clinical and pathological characteristics in patients with both IgA nephropathy (IgAN) and diabetes mellitus. Methods A total of 500 patients were recruited, including 25 patients with both IgAN and diabetes mellitus, and 475 patients with IgAN only, who were diagnosed by renal-biopsy during Jan 2015 to Jan 2017 at the First Affiliated Hospital of Zhengzhou University. The clinical and pathological data were collected and analyzed using SPSS 22.0. Propensity Score Matching was used to match and select the patients in the both groups, and thereafter the depth of the basement membrane from the matched patients were compared using electron microscopy. The data of the patients whose follow - up time was ≥3 months were retrospectively collected, and Kaplan-Meier analysis was used to compare the difference of the prognosis. Results Compared to the patients with IgAN only, patients with both IgAN and diabetes mellitus were older [(46.36±13.49) years vs (34.00±13.80) years, P<0.001], had higher level of serum triglyceride [2.06(1.52, 3.11) mmol/L vs 1.51(1.01, 2.25) mmol/L, P=0.012] and thicker basement membrane [(384.33 ± 61.20) nm vs (346.72 ± 52.65) nm, P=0.044]. The patients with both IgAN and diabetes mellitus were more prone to reach the composite endpoint [4/7(57.14％) vs 25/265(9.33％), P<0.001] and had worse prognosis (Log-Rank test, P=0.004). Conclusions IgAN patients with diabetes mellitus have different clinical, pathological characteristics and prognosis from patients with IgAN alone. These patients need to be closely monitored and actively treated.
